SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

$ISO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $ISO alert in real time by email
SC 13G/A 1 d423460dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

IsoPlexis Corporation

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

465005 106

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 465005 106

 

  1    

  NAMES OF REPORTING PERSONS

 

  Perceptive Advisors LLC

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  4,095,498

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  4,095,498

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  4,095,498

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  10.0%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IA


CUSIP No. 465005 106

 

  1    

  NAMES OF REPORTING PERSONS

 

  Joseph Edelman

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  4,095,498

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  4,095,498

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  4,095,498

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  10.0%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN


CUSIP No. 465005 106

 

  1    

  NAMES OF REPORTING PERSONS

 

  Perceptive Life Sciences Master Fund, Ltd.

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Cayman Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  2,743,213

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  2,743,213

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  2,743,213

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  6.8%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  CO


  1    

  NAMES OF REPORTING PERSONS

 

  Perceptive Credit Advisors, LLC

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  1,352,285

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  1,352,285

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,352,285

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  3.3%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  OO


  1    

  NAMES OF REPORTING PERSONS

 

  Perceptive Credit Holdings III, LP

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  1,147,336

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  1,147,336

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,147,336

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.8%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN


  1    

  NAMES OF REPORTING PERSONS

 

  PCOF EQ AIV III, LP

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

  (a)  ☐        (b)  ☒

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  204,949

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  204,949

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  204,949

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  0.5%

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN


Item 1(a).

 

   Name of Issuer:
   IsoPlexis Corporation (the “Issuer”)
Item 1(b).    Address of Issuer’s Principal Executive Offices:
   35 NE Industrial Rd
   Branford, CT 06405
Item 2(a).    Names of Persons Filing:

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

   Perceptive Advisors LLC (“Perceptive Advisors”)
   Joseph Edelman (“Mr. Edelman”)
   Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
   Perceptive Credit Advisors, LLC (“Perceptive Credit”)
   Perceptive Credit Holdings III, LP (“Perceptive Credit Holdings III”)
   PCOF EQ AIV III, LP (“PCOF”)
Item 2(b).    Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

   51 Astor Place, 10th Floor
   New York, NY 10003
Item 2(c).    Citizenship:
   Perceptive Advisors is a Delaware limited liability company
   Mr. Edelman is a United States citizen
   The Master Fund is a Cayman Islands corporation
   Perceptive Credit is a Delaware limited liability company
   Perceptive Credit Holdings III is Delaware limited partnership
   PCOF is a Delaware limited partnership
Item 2(d).    Title of Class of Securities:
   Common Stock, par value $0.001 per share (“Common Stock”)
Item 2(e).    CUSIP Number:
   465005 106


Item 3.   

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

   Not applicable.
Item 4.    Ownership.
   The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 40,351,574 shares of Common Stock outstanding as of February 6, 2023, as reported in the Issuer’s proxy statement filed on February 6, 2023.
   Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 2,743,213 shares of Common Stock. Perceptive Credit Holdings III holds directly holds 335,962 shares of Common Stock and warrants exercisable for 811,374 shares of Common Stock. PCOF holds directly 204,949 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Perceptive Credit serves as the investment manager to Perceptive Credit Holdings III and PCOF. Mr. Edelman is the managing member of Perceptive Advisors and Perceptive Credit.
Item 5.    Ownership of Five Percent or Less of a Class.
   If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
   Not applicable.
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   Not applicable.
Item 8.    Identification and Classification of Members of the Group.
   Not applicable.
Item 9.    Notice of Dissolution of Group.
   Not applicable.
Item 10.    Certification.
   By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:   February 14, 2023
PERCEPTIVE ADVISORS LLC
By:   /s/ Joseph Edelman
  Name: Joseph Edelman
  Title: Managing Member
/s/ Joseph Edelman
JOSEPH EDELMAN
PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
By:   Perceptive Advisors LLC
By:   /s/ Joseph Edelman
  Name: Joseph Edelman
  Title: Managing Member
PERCEPTIVE CREDIT ADVISORS LLC
By:   /s/ Joseph Edelman
  Name: Joseph Edelman
  Title: Managing Member
PERCEPTIVE CREDIT HOLDINGS III, LP
By:   Perceptive Credit Opportunities GP, LLC, its general partner
By:   /s/ Joseph Edelman
  Name: Joseph Edelman
  Title: Managing Member


PCOF EQ AIV III, LP
By:   PCOF EQ AIV GP, LLC, its general partner
By:   /s/ Joseph Edelman
  Name: Joseph Edelman
  Title: Managing Member
Get the next $ISO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ISO

DatePrice TargetRatingAnalyst
2/15/2022$17.00 → $12.00Overweight
Morgan Stanley
1/27/2022$20.00 → $15.00Outperform
SVB Leerink
11/19/2021$24.00Outperform
Evercore ISI Group
11/11/2021$17.00 → $20.00Outperform
SVB Leerink
11/2/2021$17.00Outperform
SVB Leerink
11/2/2021Outperform
Cowen & Co.
11/2/2021$16.00Overweight
Morgan Stanley
More analyst ratings

$ISO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

    PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis Reports Preliminary Full Year 2022 Revenue

    BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

$ISO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ISO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ISO
Leadership Updates

Live Leadership Updates

See more
  • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

    BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Financials

Live finance-specific insights

See more
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

    BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more